| abstract |
To provide a preventive and therapeutic drug for non-alcoholic hepatitis. By ingesting α-lipoic acid S-form or α-lipoic acid S-form cyclodextrin complex, the oxidative stress marker in the liver is reduced, liver damage is improved, and prevention and treatment of non-alcoholic hepatitis can be expected. . [Selection figure] None |